ARTICLE | Product Development
Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to
Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year
October 16, 2020 10:40 PM UTC
The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to a series of new MOAs.
The heart failure pipeline contains at least 18 clinical-stage programs with five readouts — all involving new mechanisms — expected over the next year. That’s on top of the two SGLT2 inhibitors that already demonstrated a benefit in Phase III in the past year...